IONS Ionis Pharmaceuticals, Inc. Common Stock

XNAS 40.15 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

IONS $40.15 —
Key stats
$40.15
52-Week Range
$39.33 – $86.74
YTD
-49.60%
IV Rank (30D)
86.82
Straddle Price
$4.53
P/C Vol Ratio
0.25
Market Cap
$6.7B
Open
$41.38
Day Range
$39.33 – $41.52
Volume
4,101,901
Prev Close
$40.42
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.94%
Beta vs SPY0.80
Cost of Equity (CAPM)8.92% (VRP-adj)
WACC8.39%
Volatility Risk Premium+66.8pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.6B
Return on Equity (TTM)-128.5%
Book / Price6.7%
Gross Margin (TTM)98.2%
FCF Margin (TTM)-64.2%
Debt / Equity3.01
Quality Score2/6 — normal (10y DCF)
SMA 50$48.22 (Market Anchor value)
SMA 20 / Bollinger Mid$43.56
Bollinger Width / SMA2025.5% (drives anchor stability)
Net Debt$1.0B
Market Cap$7B
Peers used for multiples: ABBV, AMGN, GH, JNJ, LLY, NTRA, NVS, TWST
60-Day Conviction
62%
20-Day Fair Value
≈ by Dec 3, 2026
$40.18
α +0.1% rank 65%
conviction
6%
40-Day Fair Value
≈ by Jan 1, 2027
$40.96
α +2.0% rank 62%
conviction
65%
60-Day Fair Value
≈ by Feb 1, 2027
$40.88
α +1.8% rank 67%
conviction
62%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 45.1× · 5 peers
Peer EV/EBITDA n/a 0% median 20.5× · 5 peers
Peer P/B $55.09 12% median 20.4× · 6 peers
Peer P/S $66.47 12% median 11.2× · 8 peers
Market Anchor (SMA50) $48.22 44% stability 71% (BB-width)
Options Expected (B-L 30d) $40.37 31% 22 strikes · skew -0.27
As of 2026-11-04 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$6.7B
Employees
1,402
List Date
1991-05-17
CIK
0000874015
Next Earnings
2026-11-09 (Pre-Market)
EPS Forecast
($1.22)
Headquarters
Carlsbad, CA
Homepage
https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ioni…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan5.79%-2.45%6.09%-2.80%-8.04%3.77%0.39%
Feb-11.14%5.93%-10.32%-11.30%3.30%-2.31%-4.31%
Mar-16.82%8.69%-0.58%-4.64%-7.45%-8.38%-4.86%
Apr-4.95%-5.50%0.06%-6.10%12.66%-0.49%-0.72%
May-13.35%-4.82%14.63%-12.65%5.68%1.62%-1.48%
Jun8.57%3.09%-4.45%22.93%15.83%5.19%8.53%
Jul-7.27%-1.31%0.85%4.99%7.61%-34.51%-4.94%
Aug5.66%13.42%-2.28%-7.09%-0.92%10.77%3.26%
Sep-16.73%1.77%12.00%-15.32%13.79%-25.43%-4.99%
Oct-5.06%-1.76%1.93%-1.74%12.92%-1.09%0.87%
Nov-19.70%-9.01%9.30%-7.82%12.33%-2.64%*-2.92%
Dec18.82%-6.04%-2.01%-3.16%-3.51%--0.82%
Total-48.33%-0.36%24.92%-39.94%80.03%-48.53%-5.37%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $43.36
SMA 50: $47.75
SMA 200: $66.24
Current: $40.15
EMA 12: $42.65
EMA 26: $44.14
MACD: -1.4967 | Signal: -0.0706
BEARISH
ADX (14): 29.37
TREND
+DI: 14.56
−DI: 32.39

Momentum Oscillators

RSI (14): 33.54
NEUTRAL
Stoch %K: 5.51
Stoch %D: 17.73
Williams %R: -87.40

Volume & Volatility

BB Upper: $46.18
BB Lower: $40.55
OVERSOLD
OBV: 10,088,461
Vol SMA 20: 2,860,351
Vol ROC: 71.52%
ATR: $1.79
True Range: $2.20
HV 20: 42.2%
HV 30: 36.9%
HV 60: 43.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-06T00:00:00 – 2026-11-04T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 7/10) Key Drivers:

  • Technical signals indicating a neutral trend
  • Recent news sentiment is mixed, with some positive and negative headlines Primary Risks:
  • Downtrend risk due to bearish MACD signal
  • Volatility risk as IV premium is higher than historical volatility Investment Thesis: Ionis Pharmaceuticals (IONS) has a mixed technical and fundamental profile. While the recent earnings miss and FDA trial failure have weighed on the stock, the company's pipeline and RNA-targeted drug pipelines show promise. The options market expects a moderate move by expiration, which may be influenced by upcoming catalysts. Recent News Sentiment Impact: The positive news headlines (e.g., CEO interview) have had a limited impact on the stock price due to the overall bearish sentiment from the recent earnings miss and trial failure.

Technical Analysis Trend Direction: Neutral (Short-term), Downtrend (Medium-term) Support/Resistance Levels:

  • Upper Bollinger Band: $60.82
  • Lower Bollinger Band: $51.65 Momentum Signals:
  • RSI: 52.58 (Neutral)
  • MACD Signal: -0.70 (Bearish)
  • Bollinger Bands: Neutral signal Volume Analysis:
  • Volume SMA 20: 2456675.15
  • On-Balance Volume (OBV): 48931906.99
  • Volume Rate of Change: 35.55%

News & Sentiment Analysis Recent Headlines Summary: The recent news headlines are mixed, with positive sentiment from the CEO interview and some analyst upgrades, but also negative sentiment from the earnings miss and trial failure. Sentiment Assessment: NEUTRAL Catalyst Identification:

  • Upcoming earnings date (TBD)
  • FDA approvals or rejections for RNA-targeted drug pipelines Market Narrative: The mixed technical signals and recent news headlines create a neutral market narrative, with no clear direction.

Risk & Volatility Assessment Beta Interpretation:

  • Beta: 0.19 (Low volatility) Volatility Regime:
  • Current IV premium vs historical volatility: 118.0% (High) Options Market Signals:
  • IV Rank: 64.4% (Medium)
  • Put/Call Volume Ratio: 0.60 (Bullish sentiment) Downside Protection:
  • Support levels: $51.65 (Lower Bollinger Band) and $56.23 (SMA 20)

Market Context & Positioning Sector Performance:

  • Oligonucleotide CDMO Market: Growing at a 14.64% CAGR Institutional Activity:
  • Volume patterns suggesting institutional interest in the options market Correlation Analysis:
  • Correlation with SPY: 0.05 (Low) Relative Valuation:
  • Position within trading range

Key Levels & Action Items Critical Price Levels:

  • Support levels: $51.65 (Lower Bollinger Band) and $56.23 (SMA 20) Breakout/Breakdown Levels:
  • Upper Bollinger Band: $60.82 Time-Sensitive Catalysts:
  • Upcoming earnings date (TBD) Risk Management:
  • Stop-loss levels: $54.50 and $58.00

This comprehensive analysis report provides an in-depth examination of Ionis Pharmaceuticals' stock performance, technical signals, and market context. The neutral trend direction and mixed news sentiment create a challenging environment for investors. The report highlights potential risks and opportunities, including the company's pipeline and RNA-targeted drug pipelines.

Generated
News
All IONS news →
Earnings History
23 of 23 under expected move
Avg Expected Move
9.40%
Avg Actual Move
2.75%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-24 Pre-Market 11.35% 0.29% 0.03x Within
2021-05-05 Pre-Market 10.53% 4.98% 0.47x Within
2021-08-04 Pre-Market 10.74% 0.00% 0.00x Within
2021-11-03 Pre-Market 11.37% 2.40% 0.21x Within
2022-02-24 Pre-Market 12.04% 5.73% 0.48x Within
2022-05-04 Pre-Market 10.78% 2.81% 0.26x Within
2022-08-09 Pre-Market 8.09% 3.17% 0.39x Within
2022-11-09 Pre-Market 9.94% 1.92% 0.19x Within
2023-02-22 Pre-Market 9.39% 3.74% 0.40x Within
2023-05-03 Pre-Market 7.01% 2.22% 0.32x Within
2023-08-09 Pre-Market 5.71% 1.11% 0.19x Within
2023-11-02 Pre-Market 6.56% 3.38% 0.52x Within
2024-02-21 Pre-Market 10.62% 1.85% 0.17x Within
2024-05-07 Pre-Market 5.84% 3.19% 0.55x Within
2024-08-01 Pre-Market 5.11% 3.76% 0.74x Within
2024-11-06 Pre-Market 9.79% 0.62% 0.06x Within
2025-02-19 Pre-Market 8.92% 0.44% 0.05x Within
2025-04-30 Pre-Market 10.40% 3.02% 0.29x Within
2025-07-30 Pre-Market 12.30% 4.56% 0.37x Within
2025-10-29 Pre-Market 11.32% 2.30% 0.20x Within
2026-02-25 Pre-Market 11.12% 5.29% 0.48x Within
2026-04-29 Pre-Market 7.31% 4.25% 0.58x Within
2026-07-29 Pre-Market 10.04% 2.28% 0.23x Within

Earnings calendar: this week’s reports with expected vs actual moves →

IONS Options Activity & IV Rank

IONS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 57.9%
7-DTE IV: 67.4%
Expected Move: $4.53
7-DTE Move: $4.53
Days to Exp: 16 (2026-11-20)

Options Flow

Call Volume: 227
Put Volume: 56
P/C Volume: 0.247
BULLISH
Call OI: 7,041
Put OI: 3,538
P/C OI: 0.502
Total OI: 10,579

ATM Options Pricing

ATM Call: $2.33
ATM Put: $2.20
Call %: 5.8%
Put %: 5.5%

Chain Summary

Chain Volume: 6,539
Chain OI: 52,679
Last Updated: 11/4/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 20th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
20%
vs own history
GEX tilt
-0.17
OI-weighted, today
Vanna tilt
+0.34
δ-sensitivity to IV
Charm tilt
-0.28
δ-decay vs time
Vanna tilt +0.34: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 25 ATM contracts, 11k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Nov 4 · ATM 67.5% / Wing —
30 DTE / 10d —
— pts EXTREME
as of Nov 4 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)78.1HighNov 4
IV Rank (30 DTE)86.8HighNov 4
Straddle Price (30 DTE)$4.53Nov 4
Beta Analysis

Risk Metrics

Beta: 0.5404
Alpha: -57.38%
Correlation: 0.1619
R-Squared: 2.6%
Stock Volatility: 42.9%
Market Volatility: 12.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own IONS
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$153.5M
0.09%
#268 of 6285+47.1%13F
Renaissance Technologies Hedge fund
Jim Simons
$44.4M
0.06%
#374 of 3138+83.1%13F
Millennium Management Hedge fund
Izzy Englander
$22.9M
0.02%
#1043 of 3716-72.5%13F
Rockefeller Capital Management Family office
Rockefeller family
$304K
0.00%
#2365 of 4729-7.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

IONS Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 162,517,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

535 filers792,815,217 shares$16.46B value487.84% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 31,635,956 $1.96B 11.93% 19.47% 2026-06-30
2 Capital World Investors 21,669,226 $1.72B 10.44% 13.33% 2026-06-30
3 Vanguard Group Inc Custodian 16,440,459 $1.30B 7.90% 10.12% 2025-12-31
4 BlackRock, Inc. Custodian 22,129,660 $866.53M 5.27% 13.62% 2026-06-30
5 Wellington Management Group LLP Custodian 19,218,415 $624.64M 3.80% 11.83% 2026-06-30
6 Vanguard Portfolio Management LLC 7,859,529 $623.18M 3.79% 4.84% 2026-06-30
7 Vanguard Capital Management LLC 7,211,497 $571.80M 3.47% 4.44% 2026-06-30
8 Two Sigma Investments, LP Custodian 6,252,342 $495.75M 3.01% 3.85% 2026-06-30
9 Royal Bank of Canada Custodian 6,282,479 $490.37M 2.98% 3.87% 2026-06-30
10 State Street Corp 19,359,848 $367.07M 2.23% 11.91% 2026-06-30
11 T. Rowe Price Investment Management, Inc. 3,959,372 $313.94M 1.91% 2.44% 2026-06-30
12 Geode Capital Management, LLC Custodian 3,584,024 $294.75M 1.79% 2.21% 2026-06-30
13 T. Rowe Price Associates, Inc. 3,184,500 $252.50M 1.53% 1.96% 2026-06-30
14 DEERFIELD MANAGEMENT COMPANY, L.P. 61,979,669 $250.07M 1.52% 38.14% 2026-06-30
15 JPMorgan Chase & Co Custodian 3,224,717 $217.07M 1.32% 1.98% 2026-06-30
16 Artisan Partners Limited Partnership 2,640,024 $209.33M 1.27% 1.62% 2026-06-30
17 Tweedy, Browne Co LLC 2,280,311 $180.81M 1.10% 1.40% 2026-06-30
18 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Custodian 42,554,672 $179.23M 1.09% 26.18% 2026-06-30
19 Deep Track Capital, LP 2,200,000 $174.44M 1.06% 1.35% 2026-06-30
20 Goldman Sachs Group Inc Custodian 2,109,945 $167.30M 1.02% 1.30% 2026-06-30
21 BAKER BROS. ADVISORS LP 2,047,727 $162.36M 0.99% 1.26% 2026-06-30
22 American Century Companies, Inc. 1,947,076 $154.38M 0.94% 1.20% 2026-06-30
23 Citadel Advisors LLC Custodian 86,703,284 $153.45M 0.93% 53.35% 2026-06-30
24 TENOR CAPITAL MANAGEMENT Co., L.P. 94,682,000 $147.77M 0.90% 58.26% 2026-06-30
25 Franklin Resources, Inc. Custodian 1,623,377 $128.72M 0.78% 1.00% 2026-06-30
29 filers$394.56M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $103.11M 26.13% 2026-06-30
2 Caption Management, LLC $49.95M 12.66% 2026-06-30
3 Jane Street Group, LLC Custodian $44.05M 11.16% 2026-06-30
4 Ikarian Capital, LLC $31.72M 8.04% 2026-06-30
5 Integral Health Asset Management, LLC $23.79M 6.03% 2026-06-30
6 Millennium Management LLC Custodian $20.42M 5.17% 2026-06-30
7 Citadel Advisors LLC Custodian $18.43M 4.67% 2026-06-30
8 JPMorgan Chase & Co Custodian $13.31M 3.37% 2026-06-30
9 Citigroup Inc. Custodian $12.00M 3.04% 2026-06-30
10 IMC-Chicago, LLC Custodian $10.13M 2.57% 2026-06-30
11 BOOTHBAY FUND MANAGEMENT, LLC $9.49M 2.41% 2026-06-30
12 SIG BROKERAGE, LP $8.52M 2.16% 2026-06-30
13 Lighthouse Investment Partners, LLC $7.93M 2.01% 2026-06-30
14 D. E. Shaw & Co., Inc. Custodian $6.94M 1.76% 2026-06-30
15 GROUP ONE TRADING LLC Custodian $5.71M 1.45% 2026-06-30
16 Bank of Montreal Custodian $4.95M 1.25% 2026-06-30
17 NOMURA HOLDINGS INC $4.71M 1.19% 2026-06-30
18 Simplex Trading, LLC Custodian $3.39M 0.86% 2026-06-30
19 DLD Asset Management, LP $3.17M 0.80% 2026-06-30
20 J. Goldman & Co LP $3.14M 0.80% 2026-06-30
21 TUDOR INVESTMENT CORP ET AL $2.85M 0.72% 2026-06-30
22 Walleye Capital LLC $2.20M 0.56% 2026-06-30
23 Point72 Asset Management, L.P. $1.61M 0.41% 2026-06-30
24 Wolverine Trading, LLC Custodian $1.55M 0.39% 2025-09-30
25 WOLVERINE ASSET MANAGEMENT LLC $792.90K 0.20% 2026-06-30
20 filers$250.74M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $65.18M 26.00% 2026-06-30
2 Jane Street Group, LLC Custodian $43.07M 17.18% 2026-06-30
3 Citadel Advisors LLC Custodian $30.65M 12.22% 2026-06-30
4 Caption Management, LLC $27.43M 10.94% 2026-06-30
5 Ikarian Capital, LLC $23.79M 9.49% 2026-06-30
6 JPMorgan Chase & Co Custodian $13.31M 5.31% 2026-06-30
7 IMC-Chicago, LLC Custodian $9.90M 3.95% 2026-06-30
8 BOOTHBAY FUND MANAGEMENT, LLC $7.30M 2.91% 2026-06-30
9 SIG BROKERAGE, LP $6.54M 2.61% 2026-06-30
10 Simplex Trading, LLC Custodian $5.15M 2.05% 2026-06-30
11 LMR Partners LLP $4.08M 1.63% 2026-06-30
12 Barclays PLC Custodian $3.96M 1.58% 2026-06-30
13 WOLVERINE ASSET MANAGEMENT LLC $2.78M 1.11% 2026-06-30
14 GROUP ONE TRADING LLC Custodian $2.25M 0.90% 2026-06-30
15 PEAK6 LLC $1.61M 0.64% 2026-06-30
16 Citigroup Inc. Custodian $1.43M 0.57% 2026-06-30
17 Point72 Asset Management, L.P. $1.10M 0.44% 2026-06-30
18 Wolverine Trading, LLC Custodian $686.40K 0.27% 2025-09-30
19 TUDOR INVESTMENT CORP ET AL $269.59K 0.11% 2026-06-30
20 Walleye Capital LLC $253.73K 0.10% 2026-06-30

IONS Insider Trading (Form 4)

Latest: 2026-10-19
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-19 Shannon L. Devers EVP, Chief Human Resources Ofc Mixed +1,463 $43.54 -$59.1K EDGAR
2026-10-19 Eric Swayze EVP Research Mixed +72 $43.54 -$2.3K EDGAR
2026-09-02 C Frank Bennett EVP, Chief Scientific Officer Other (J) +110 $51.31 $5.6K EDGAR
2026-09-02 Brian Birchler EVP, Corp and Development Ops Other (J) +58 $51.31 $3.0K EDGAR
2026-09-02 Patrick R. O'Neil EVP CLO & General Counsel Other (J) +63 $51.31 $3.2K EDGAR
2026-09-02 Brett P Monia Chief Executive Officer Other (J) +98 $51.31 $5.0K EDGAR
2026-07-31 Michael R Hayden Director Buy (P) +20,000 $52.94 $1.06M EDGAR
2026-07-17 Ludwig Hantson Director Grant (A) +3,399 RSU — EDGAR
2026-07-17 Peter N Reikes Director Grant (A) +3,399 RSU — EDGAR
2026-07-17 Joan E Herman Director Exer (M) +5,220 — EDGAR
2026-07-17 Spencer R Berthelsen Director Exer (M) +5,220 — EDGAR
2026-07-09 Holly B. Kordasiewicz EVP, Chief Development Officer Sell (S) −362 $84.30 -$30.5K EDGAR
2026-07-09 Allene M. Diaz Director Mixed — $66.26 -$387.3K EDGAR
2026-07-09 C Frank Bennett EVP, Chief Scientific Officer Mixed −5,536 $84.95 -$1.74M EDGAR
2026-07-06 Spencer R Berthelsen Director Grant (A) +7,670 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

IONS Insider Holdings

22 insiders · @ $40.15
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Elizabeth L Hougen EVP, Finance & CFO 254,221 $10.21M -$27.72M 58 2026-03-18
2 Brett P Monia Chief Executive Officer 242,760 $9.75M -$62.52M 76 2026-09-02
3 Spencer R Berthelsen Director 161,303 $6.48M -$4.88M 28 2026-07-17
4 Brian Birchler EVP, Corp and Development Ops 102,883 $4.13M -$4.04M 21 2026-09-02
5 Richard S Geary EVP, Chief Development Officer 77,957 $3.13M -$23.74M 60 2025-11-07
6 Michael R Hayden Director 73,298 $2.94M $1.72M 21 2026-07-31
7 Eugene Schneider EVP, Chf Clinical Develop Ofcr 63,890 $2.57M -$5.94M 26 2026-03-23
8 C Frank Bennett EVP, Chief Scientific Officer 60,128 $2.41M -$31.71M 72 2026-09-02
9 Patrick R. O'Neil EVP CLO & General Counsel 59,205 $2.38M -$30.73M 84 2026-09-02
10 Joseph H Wender Director 52,035 $2.09M -$10.14M 26 2025-12-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

IONS Board & Officers

As of SEC filings through Oct 19, 2026

Directors 9

Officers 12

Changes in the last 10 years (42)
Jun 4, 2026Ludwig Hantson became a director
Mar 3, 2026The company announced the departure of Joseph H Wender from the board in an SEC filing
Mar 3, 2026The company announced the departure of B Lynne Parshall from the board in an SEC filing
Dec 21, 2025Holly B. Kordasiewicz became EVP, Chief Development Officer
Oct 17, 2024Shannon L. Devers listed as EVP, Chief Human Resources Ofc (previously EVP, Chief Human Resourses Ofc) in SEC filings
Sep 29, 2024Shannon L. Devers became EVP, Chief Human Resourses Ofc
Feb 26, 2024Kyle Jenne became EVP, Chf GL Pdt Str Ofcr
Dec 14, 2023Michael J. Yang became a director
Jul 6, 2023Joseph Loscalzo first listed as a director in an SEC filing
Mar 14, 2023Brian Birchler became EVP, Corp and Development Ops
Jan 5, 2023Onaiza Cadoret-Manier listed as EVP, Chf GL Pdt Str & Oper Ofc (previously EVP, Chf Corp Dev and Cml Offc) in SEC filings
Oct 18, 2022Eugene Schneider listed as EVP, Chf Clinical Develop Ofcr (previously EVP, Chf Clinical Develop Offc) in SEC filings
Jul 15, 2022The company announced the departure of Frederick T Muto from the board in an SEC filing
Apr 19, 2022Joseph Baroldi listed as EVP, Chief Business Officer (previously Chief Business Officer) in SEC filings
Jan 31, 2022Joseph Baroldi became Chief Business Officer
Jan 5, 2022Richard S Geary listed as EVP, Chief Development Officer (previously EVP, Chief Development Offc) in SEC filings
Jan 5, 2022Patrick R. O'Neil listed as EVP CLO & General Counsel (previously EVP & General Counsel) in SEC filings
Jan 5, 2022Onaiza Cadoret-Manier listed as EVP, Chf Corp Dev and Cml Offc (previously Chief Corp Dev and Cml Officer) in SEC filings
Nov 19, 2021The company announced the departure of Peter N Reikes from the board in an SEC filing
Sep 2, 2021C Frank Bennett listed as EVP, Chief Scientific Officer (previously Chief Scientific Officer) in SEC filings
Not reported recently (5)
  • Onaiza Cadoret-Manier · Last reported as EVP, Chf GL Pdt Str & Oper Ofc in an SEC filing dated Sep 4, 2024
  • Stanley T Crooke · Last reported as a director in an SEC filing dated Jan 28, 2021
  • Breaux Castleman · Last reported as a director in an SEC filing dated Jul 6, 2020
  • Damien McDevitt · Last reported as Chief Business Officer in an SEC filing dated Jul 17, 2019
  • Sarah Boyce · Last reported as Chief Business Officer in an SEC filing dated Jan 17, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

IONS Proposed Insider Sales (Form 144)

Latest: 2026-10-16
Last 30d: 1 filing · $60K notice value  ·  Last 90d: 1 filing · $60K notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Devers Shannon L. (1, $60K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-16 Devers Shannon L. Officer 1,357 $59.7K 2026-10-16 Morgan Stanley Smith Barney — EDGAR
2026-07-07 Diaz Allene M. Director 10,111 $863.6K 2026-07-07 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-07-07 Kordasiewicz Holly B. Officer 1,287 $108.5K 2026-07-07 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-07-07 BENNETT C FRANK Officer 67,386 $5.72M 2026-07-07 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-07-01 KLEIN JOSEPH III Director 11,518 $910.4K 2026-07-01 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-06-26 Baroldi Mariana Member of immediate family of any of the foregoing 5,635 $451.7K 2026-06-26 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-06-26 O'NEIL PATRICK R. Officer 3,069 $245.5K 2026-06-26 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-06-26 Schneider Eugene Officer 47,884 $3.88M 2026-06-26 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-06-25 Swayze Eric Officer 10,602 $839.3K 2026-06-25 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2026-06-15 BERTHELSEN SPENCER R Director 8,000 $587.9K 2026-06-15 Fidelity Brokerage Services LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-28 0001140361-26-023093 EDGAR
2026-04-29 0001140361-26-017637 EDGAR
2026-04-21 0001140361-26-015801 EDGAR
2026-03-09 0001140361-26-008340 EDGAR
2026-02-25 0001140361-26-006718 EDGAR
2026-01-12 0001140361-26-000893 EDGAR
2026-01-07 0001140361-26-000435 EDGAR
2025-11-17 0001193125-25-284609 EDGAR
2025-11-10 0001140361-25-041225 EDGAR
2025-10-29 0001140361-25-039650 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-26 0000874015-26-000115 EDGAR
2025-02-19 0000874015-25-000089 EDGAR
2024-02-21 0000874015-24-000116 EDGAR
2023-02-22 0000874015-23-000105 EDGAR
2022-02-25 0000874015-22-000079 EDGAR
2021-02-24 0000874015-21-000056 EDGAR
2020-03-02 0001140361-20-004500 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-04-29 0000874015-26-000177 EDGAR
2025-10-29 0000874015-25-000266 EDGAR
2025-07-30 0000874015-25-000167 EDGAR
2025-04-30 0000874015-25-000123 EDGAR
2024-11-06 0000874015-24-000232 EDGAR
2024-08-01 0000874015-24-000187 EDGAR
2024-05-07 0000874015-24-000142 EDGAR
2023-11-02 0000874015-23-000209 EDGAR
2023-08-09 0000874015-23-000186 EDGAR
2023-05-03 0000874015-23-000136 EDGAR
ETF Holders
116 ETFs hold IONS
25 shown · $1.07B total exposure · 0.10% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $223.9M — 2026-09-30
2 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.09% $158.6M — 2026-09-30
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 1.06% $111.4M $10.6B 2026-11-03
4 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.20% $88.1M — 2026-09-30
5 VXF Vanguard Extended Market ETF Vanguard 0.09% $83.7M — 2026-09-30
6 CGGR Capital Group Growth ETF Capitalgroup 0.24% $60.0M $25.2B 2026-11-02
7 SCHA Schwab U.S. Small-Cap ETF Nport 0.26% $59.6M — 2026-05-31
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.45% $50.2M $11.4B 2026-11-03
9 IWP iShares Russell Mid-Cap Growth ETF iShares (BlackRock) 0.19% $35.3M $18.5B 2026-11-03
10 SCHM Schwab U.S. Mid-Cap ETF Nport 0.23% $33.5M — 2026-05-31
11 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.05% $28.3M $58.8B 2026-11-03
12 IWF iShares Russell 1000 Growth ETF iShares (BlackRock) 0.02% $23.6M $120.5B 2026-11-03
13 VHT Vanguard Health Care ETF Vanguard 0.10% $21.4M — 2026-09-30
14 CGMM Capital Group U.S. Small and Mid Cap ETF Capitalgroup 0.41% $14.9M $3.6B 2026-11-02
15 VONG Vanguard Russell 1000 Growth ETF Vanguard 0.02% $11.3M — 2026-09-30
16 TMSL T. Rowe Price Small-Mid Cap ETF Nport 0.35% $9.4M — 2026-06-30
17 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $8.9M $97.0B 2026-11-03
18 QMOM Alpha Architect U.S. Quantitative Momentum ETF Nport 1.93% $8.6M — 2026-06-30
19 NUSC Nuveen ESG Small-Cap ETF Nport 0.61% $7.8M — 2026-07-31
20 SCHB Schwab U.S. Broad Market ETF Nport 0.02% $7.4M — 2026-05-31
21 VT Vanguard Total World Stock ETF Vanguard 0.01% $6.6M — 2026-09-30
22 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.21% $5.7M — 2026-07-31
23 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.13% $5.6M $4.3B 2026-11-03
24 FFOX FundX Future Fund Opportunities ETF Nport 2.06% $5.0M — 2026-06-30
25 IYH iShares U.S. Healthcare ETF iShares (BlackRock) 0.10% $4.6M $4.9B 2026-11-03
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.48
TTM Revenue
$874.09M
TTM Net Income
$-565.17M
TTM Op. Cash Flow
$-496.43M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$267.95M$-114.65M$-0.69$565.53M
Q1 '262026-03-31$246.09M$-92.53M$-0.56$-792.82M
Q4 '252025-12-31$203.33M$-229.39M$-1.43$-137.71M
Q3 '252025-09-30$156.72M$-128.61M$-0.80$-131.44M
Q2 '252025-06-30$452.05M$123.55M$0.70$151.34M
Q1 '252025-03-31$131.61M$-146.94M$-0.93$-150.78M
Q4 '242024-12-31$226.58M$-104.35M$-0.66$-116.14M
Q3 '242024-09-30$133.81M$-140.48M$-0.95$-114.99M
Q2 '242024-06-30$225.25M$-66.27M$-0.45$-119.88M
Q1 '242024-03-31$119.50M$-142.80M$-0.98$-149.94M
Q4 '232023-12-31$324.50M$-9.26M$-0.06$32.87M
Q3 '232023-09-30$144.21M$-147.41M$-1.03$-109.02M
Q2 2026 • period ending 2026-06-30 • filed 2026-07-29
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
14.84
P/S
7.46
EV/EBITDA
—
EV/Sales
8.58
ROE
-128.5%
ROA
-18.9%
Div Yield
0.00%
FCF Yield
-7.61%
Debt/Equity
3.01
Current Ratio
—
Market Cap
$6.53B
as of 2026-11-04
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
20.65M
SI % of Float
12.61%
Days to Cover
7.65
Short Vol Ratio
45.8%
Free Float
163.72M
Float %
98.5%
Short interest 2026-10-15 • Short volume 2026-11-04 • Float 2026-08-24